Investment Rating - The investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights the robust performance of companies in the toy and commercial real estate sectors, with significant growth in revenue and profits driven by strategic initiatives and market conditions [4][31][51]. Summary by Sections 1. Toy Industry - The company "Blok" achieved a revenue of 1.575 billion yuan in H2 2025, representing a year-on-year increase of 31.9%, with an adjusted net profit of 355 million yuan, up 21.3% [13][16]. - The company has commercialized 29 IPs by H2 2025, with a total of 73 authorized IPs in reserve, indicating a strong focus on product matrix expansion [17]. - LEGO reported a record revenue of 83.53 billion Danish kroner in 2025, a 12.4% increase year-on-year, with a significant rise in operating profit and net profit [31][36]. 2. Commercial Real Estate - Swire Properties reported a revenue of 16.041 billion HKD in 2025, an 11% increase year-on-year, with a substantial rise in net profit by 27% to 8.62 billion HKD [51][54]. - The retail sector in Hong Kong showed positive growth, with a rental reversal and strong sales performance in early 2026, driven by improved consumer sentiment [52][58]. - The report notes that geopolitical tensions in the Middle East may lead to increased capital inflow into Hong Kong real estate, positioning it as a key investment destination for sovereign wealth funds [60][61]. 3. Beauty Industry - In February 2026, the beauty category on Douyin saw a GMV of 21.85 billion yuan, with a slight decline of 1.13% year-on-year, indicating a slowdown in growth compared to previous years [63][66]. - The report emphasizes the differentiation in growth rates between instant gratification categories like makeup and longer-term trust-based categories like skincare, suggesting a need for brands to adapt their strategies accordingly [64][65]. 4. Market Performance - The Hong Kong stock market saw the consumer services index underperforming, while the retail sector outperformed the market, indicating varying performance across sectors [4][12].

Key Points Summary Company and Industry Involved - The report focuses on the company "金达威" (Jindawi) and its operations in the dietary supplement industry, particularly in the production of coenzyme Q10 and contract manufacturing for brands like 多特倍斯 (Duotebei) and others [1][2]. Core Insights and Arguments 1. **Coenzyme Q10 Pricing**: The current price of coenzyme Q10 is considered reasonable, with a decrease noted in December followed by a recovery in January and February due to strong demand. The expectation for 2026 is an increase in volume but a decrease in price, with a target gross margin of 45%-50% [1][1]. 2. **Contract Manufacturing (VB)**: - Anticipated acceleration in revenue from the VB segment, which currently only produces tablets and hard capsules, with soft capsule production expected to start in April [1][1]. - The VB manufacturing process and delivery timelines have been clarified, indicating self-sustaining capabilities that allow participation in large project tenders. Orders have been received from clients like Duotebei, Walmart, and iHerb, although the current volume is small [1][1]. 3. **Brand Strategy**: - Duotebei in the U.S. aims for modest growth, influenced by consumer trends. In China, the focus for 2025 will be on return on investment, with significant investments planned for 2026 to enhance brand penetration and volume, while relaxing profit expectations [1][1]. 4. **Cross-Border Product Management**: The company is leveraging its advantages in cross-border product management, particularly through platforms like Douyin [2][1]. 5. **Investment in U.S. Contract Manufacturing**: Increased investment in U.S. contract manufacturing is highlighted, showcasing a strong competitive edge across the entire supply chain, despite lower margins downstream [2][1]. Other Important but Potentially Overlooked Content 1. **Change in Fund Utilization**: - Plans to establish a smart factory focusing on proprietary health products, potentially utilizing the existing brand "金乐心" (Jinlexin), targeting affordable products in lower-tier cities, specifically in coenzyme Q10 and PQQ [3][1]. - A new project focusing on algae oil, particularly EPA, aimed at vascular health, is also mentioned [3][1]. 2. **Market Dynamics**: The report notes that Douyin's special governance on cross-border VDS is expected to improve competitive dynamics in 2026, alongside increased domestic investments by Duotebei [3][1]. 3. **Empowerment through Smart Factory**: The smart factory in Inner Mongolia is positioned to empower the consumer end, focusing on lower-tier markets [3][1].

Core Viewpoint - The report from Tianfeng Securities highlights that Jindawei's main business includes health products, coenzyme Q10, and vitamin series, with a projected revenue of 1.728 billion yuan in H1 2025, representing a year-on-year increase of 13.5%, and a net profit attributable to the parent company of 247 million yuan, reflecting a significant year-on-year growth of 90.1% [1] Group 1: Company Performance - The health product market is continuously expanding, driven by increasing health consumption demand [1] - In the short term, the company expects stable growth in coenzyme Q10 and a surge in domestic demand for its health product brand, Duote Beisi, indicating a continuation of high growth in H1 2025 [1] - For the medium to long term, the company has a clear growth path, leveraging its synthetic biology technology platform to incubate high-value new products like EPA, potentially replicating the success of coenzyme Q10 [1] Group 2: Investment and Growth Projections - The company plans to use funds from convertible bonds for the expansion and renovation of coenzyme Q10 production, as well as projects for 30,000 tons of allulose and 5,000 tons of inositol, which are expected to provide new growth points for performance [1] - The brandization of the company's health products is also undergoing continuous upgrades and implementation [1] - Projected net profits attributable to the parent company for 2025-2027 are estimated at 440 million, 650 million, and 790 million yuan, with growth rates of 29%, 47%, and 22% respectively [1] Group 3: Valuation and Market Position - The company is compared to peers such as Tongrentang and Ruoyuchen, with a PEG ratio of 1.1 for 2026, corresponding to a PE of 35X [1] - The target market value is set at 15.7 billion yuan, with a target price of 25.7 yuan, maintaining a "buy" rating [1]